Start Your Journey in Street Fighter™: Duel with the Beloved Fighters this February
According to the publisher A PLUS Japan, the pre-registration has started on App Store and Google Play on Jan. 31st. The game is available in English, French, German, Spanish, and Portuguese. Players in most of Europe, Latin America, Middle East, and North Africa can now pre-register via the Official Website.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230203005211/en/
Photo: A PLUS JAPAN INC.
The game has a big roster of fighters and offers game mechanics to improve them. In this game, everyone has a chance to get their favorite fighter and build them to the top. With this unique character system, you will gain a sense of accomplishment when each of the fighters levels up.
Street Fighter ™: Duel brings back the iconic stages of the franchise, such as the airfield, bathhouse, night scene, etc. Also, the game has optimized the visual effects for mobile phones and made the stages more realistic and vivid.
The gameplay is optimized for mobile platforms with game modes such as character training and arena. Mechanics like auto combos and EX-Move are also added to make the game enjoyable for everyone.
These new features will bring a unique combat experience to the players in the official version that will be released this February.
Pre-registration link:
https://play.google.com/store/apps/details?id=com.sfdapj.eu
https://itunes.apple.com/jp/app/id6444200827
©CAPCOM CO., LTD. ALL RIGHTS RESERVED.
About the publisher:
About A PLUS JAPAN INC.
A PLUS JAPAN INC. focuses on Japanese anime-based mobile game development and publishing. They have a solid long-term partnership globally with several anime IPs and broadcast/distribution channels. Under the mission of “Sharing joy with the world”, they continue to get exciting games derived from anime to players all over the world.
Community:
Twitter: https://twitter.com/sfduelgame
Facebook: https://www.facebook.com/Street-Fighter-Duel-100523756210620/
Discord: https://discord.com/invite/xVHGbBn7
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005211/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics13.5.2025 15:05:00 EEST | Press release
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO–biotech partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513574699/en/ Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics. The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, acce
KnowBe4 Report Reveals Security Training Reduces Global Phishing Click Rates by 86%13.5.2025 15:00:00 EEST | Press release
KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today launched its “Phishing by Industry Benchmarking Report 2025” which measures an organization’s Phish-prone™ Percentage (PPP) — the percentage of employees likely to fall for social engineering or phishing attacks, indicating the organization’s overall susceptibility to phishing threats. This year’s report found a global average baseline PPP of 33.1%, meaning a third of employees interact with phishing simulations before taking part in best-practice security awareness training (SAT). The data underscores the significant impact of SAT in mitigating risk. The rapid decline in the global PPP following the implementation of training — falling by 40% in just three months and by a total of 86% after 12 months — demonstrates that ongoing, effective training leads to lasting behavior change and a substantial reduction in vulnerability to cybersecurity threats. This highlights the critic
Armis Announces New Global Technology Integration Partners to Bolster Organizations’ Cyber Resilience13.5.2025 15:00:00 EEST | Press release
Armis, the cyber exposure management & security company, today announced that it has added 10 global technology integration partners over the past quarter. These integrations increase the functionality and efficiency of organizations’ existing technology stacks with added benefits from Armis’ platform and solutions. “Relying on siloed security solutions is no longer enough to gain a comprehensive, real-time understanding of an organization’s attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “Integrating Armis’ best-in-class platform with other leading vendors’ offerings empowers businesses to consolidate their technology stacks. By driving greater value in their security investments, organizations can ensure their entire attack surface is continuously defended and managed.” New Armis global technology integration partners include AnzenOT, Brinqa, ColorTokens, EasyVista, SaltyCloud, Salvador Tech, SIGA, Spectro Cloud, Stellar Cyber, and Synqly. From compliance to network
Kyriba Unveils Agentic AI TAI to Transform Finance with Security, Compliance & Trust13.5.2025 14:35:00 EEST | Press release
Kyriba, a global leader in liquidity performance, today introduced its agentic AI solution, TAI – a significant advancement in the safe, compliant use of generative AI in finance operations to improve productivity and efficiency amid continued economic uncertainty. Powered by Kyriba's embedded Large Language Model (LLM) and over 20 years of unmatched global liquidity data, TAI simplifies complex workflows, identifies risks with predictive analytics, and enhances data-driven decision-making across treasury, payments, risk management and working capital. Poised to transform finance and treasury operations without relying on third-party LLM integrations, TAI is a key component of Kyriba’s Trusted AI portfolio. This platform-wide approach prioritizes industry-leading data privacy while empowering enterprise leaders to make faster, smarter decisions with human judgement and responsibility at the center. Kyriba’s approach directly addresses the "Trust Gap" – the growing divide between the pr
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference13.5.2025 13:01:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 1 year following the event. About BeiGene BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom